Collagenase-3 (MMP-13) Expression in Cutaneous Malignant Melanoma

Abstract

Background

Matrix metalloproteases (MMPs), enzymes with the ability to degrade the extracellular matrix, play an important role in tissue invasion by cutaneous malignant melanoma (CMM). One specific MMP, collagenase-3 (MMP-13), is thought to have a key function in the activation of MMP.

Aims

To evaluate the expression of MMP-13 in CMM and assess its possible relationship to clinical and pathological parameters.

Methods

MMP-13 expression was analyzed in 51 paraffin-embedded tumor samples from patients with invasive CMM, ten samples from in situ melanomas, and in eight samples from benign lesions (three dermal melanocytic nevi, three compound melanocytic nevi and two atypical melanocytic nevi) using immunohistochemical techniques. The median follow-up period in patients with invasive CMM was 50 months.

Results

Benign lesions were consistently negative for MMP-13, whereas three of the ten in situ melanomas (30%) and 23 of the 51 invasive CMMs (45%) showed positive immunostaining for MMP-13. The percentage of MMP-13-positive tumors correlated significantly and positively with the mitotic index (p=0.002) in invasive CMM. However, our results did not show any significant association between tumoral MMP-13 expression and relapse-free survival in patients with invasive CMM.

Conclusions

MMP-13 appears to be a factor associated with tumor aggressiveness in CMM. It seems to eliminate an important barrier not only against tumoral invasion but also against proliferation.

Keywords

Collagenase-3 Melanoma Tumor invasion Metalloproteases

References

Armstrong

B.K.

, Kricker

. Cutaneous melanoma. Cancer Surv 1994; 19–20: 219–40.

Boring

C.C.

, Squires

T.S.

, Tong

. Cancer statistics, 1993. CA Cancer J Clin 1993; 43: 7–26.

Merrill

R.M.

, Feuer

E.J.

. Risk-adjusted cancer-incidence rates (United States). Cancer Causes Control 1996; 7: 544–52.

Schrick

J.J.

, Onuchic

L.F.

, Reeders

S.T.

. Characterization of the human homologue of the mouse Tg737 candidate polycystic kidney disease gene. Hum Mol Genet 1995; 4: 559–67.

Breslow

, Macht

S.D.

. Evaluation of prognosis in stage I cutaneous melanoma. Plast Reconstr Surg 1978; 61: 342–6.

Cochran

A.J.

. Prediction of outcome for patients with cutaneous melanoma. Pigment Cell Res 1997; 10: 162–7.

Massi

, Borgognoni

, Franchi

. Thick cutaneous malignant melanoma: a reappraisal of prognostic factors. Melanoma Res 2000; 10: 153–64.

Bogenrieder

, Herlyn

. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 2003; 22: 6524–36.

Airola

, Karonen

, Vaalamo

. Expression of collagenases-1 and –3 and their inhibitors TIMP-1 and –3 correlates with the level of invasion in malignant melanomas. Br J Cancer 1999; 80: 733–43.

10.

Nikkola

, Vihinen

, Vlaykova

. High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma. Int J Cancer 2002; 97: 432–8.

11.

Hoyhtya

, Hujanen

, Turpeenniemi-Hujanen

. Modulation of type-IV collagenase activity and invasive behavior of metastatic human melanoma (A2058) cells in vitro by monoclonal antibodies to type-IV collagenase. Int J Cancer 1990; 46: 282–6.

12.

Montgomery

A.M.

, De Clerck

Y.A.

, Langley

K.E.

. Melanoma-mediated dissolution of extracellular matrix: contribution of urokinase-dependent and metalloproteinase-dependent proteolytic pathways. Cancer Res 1993; 53: 693–700.

13.

Brooks

P.C.

, Stromblad

, Sanders

L.C.

. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 1996; 85: 683–93.

14.

Vaisanen

, Tuominen

, Kallioinen

. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. J Pathol 1996; 180: 283–9.

15.

MacDougall

J.R.

, Bani

M.R.

, Lin

. The 92-kDa gelatinase B is expressed by advanced stage melanoma cells: suppression by somatic cell hybridization with early stage melanoma cells. Cancer Res 1995; 55: 4174–81.

16.

Nikkola

, Vihinen

, Vlaykova

. High collagenase-1 expression correlates with a favourable chemoimmunotherapy response in human metastatic melanoma. Melanoma Res 2001; 11: 157–66.

17.

Baronas-Lowell

, Lauer-Fields

J.L.

, Borgia

J.A.

. Differential modulation of human melanoma cell metalloproteinase expression by alpha2beta1 integrin and CD44 triple-helical ligands derived from type IV collagen. J Biol Chem 2004; 279: 43503–13.

18.

Kurschat

, Zigrino

, Nischt

. Tissue inhibitor of matrix metalloproteinase-2 regulates matrix metalloproteinase-2 activation by modulation of membrane-type 1 matrix metalloproteinase activity in high and low invasive melanoma cell lines. J Biol Chem 1999; 274: 21056–62.

19.

Hofmann

U.B.

, Westphal

J.R.

, Zendman

A.J.

. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. J Pathol 2000; 191: 245–56.

20.

Saad

, Gottlieb

D.J.

, Bradstock

K.F.

. Cancer cell-associated fibronectin induces release of matrix metalloproteinase-2 from normal fibroblasts. Cancer Res 2002; 62: 283–9.

21.

Vaisanen

, Kallioinen

, Taskinen

P.J.

. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J Pathol 1998; 186: 51–8.

22.

Freije

J.M.

, Diez-Itza

, Balbin

. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem 1994; 269: 16766–73.

23.

Uria

J.A.

, Balbin

, Lopez

J.M.

. Collagenase-3 (MMP-13) expression in chondrosarcoma cells and its regulation by basic fibroblast growth factor. Am J Pathol 1998; 153: 91–101.

24.

Johanson

, Fernstrom

. Percutaneous uptake rate of 2-butoxyethanol in the guinea pig. Scand J Work Environ Health 1986; 12: 499–503.

25.

Cazorla

, Hernandez

, Nadal

. Collagenase-3 expression is associated with advanced local invasion in human squamous cell carcinomas of the larynx. J Pathol 1998; 186: 144–50.

26.

Etoh

, Inoue

, Yoshikawa

. Increased expression of collagenase-3 (MMP-13) and MT1-MMP in oesophageal cancer is related to cancer aggressiveness. Gut 2000; 47: 50–6.

27.

del Casar Lizcano

J.M.

, Vizoso Pineiro

, Gonzalez Sanchez

L.O.

. [Expression and clinical significance of collagenase-3 (MMP-13) in gastric cancer]. Gastroenterol Hepatol 2003; 26: 1–7.

28.

Elnemr

, Yonemura

, Bandou

. Expression of collagenase-3 (matrix metalloproteinase-13) in human gastric cancer. Gastric Cancer 2003; 6: 30–8.

29.

Lindy

, Konttinen

Y.T.

, Sorsa

. Matrix metalloproteinase 13 (collagenase 3) in human rheumatoid synovium. Arthritis Rheum 1997; 40: 1391–9.

30.

Knauper

, Lopez-Otin

, Smith

. Biochemical characterization of human collagenase-3. J Biol Chem 1996; 271: 1544–50.

31.

Ashworth

J.L.

, Murphy

, Rock

M.J.

. Fibrillin degradation by matrix metalloproteinases: implications for connective tissue remodelling. Biochem J 1999; 340(Pt 1): 171–81.

32.

Cowell

, Knauper

, Stewart

M.L.

. Induction of matrix metalloproteinase activation cascades based on membrane-type 1 matrix metalloproteinase: associated activation of gelatinase A, gelatinase B and collagenase 3. Biochem J 1998; 331(Pt 2): 453–8.

33.

Johansson

, Vaalamo

, Grenman

. Collagenase-3 (MMP-13) is expressed by tumor cells in invasive vulvar squamous cell carcinomas. Am J Pathol 1999; 154: 469–80.

34.

Nielsen

B.S.

, Rank

, Lopez

J.M.

. Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas. Cancer Res 2001; 61: 7091–100.

35.

Leeman

M.F.

, McKay

J.A.

, Murray

G.I.

. Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer. J Clin Pathol 2002; 55: 758–62.

36.

Thompson

J.A.

. The revised American Joint Committee on Cancer staging system for melanoma. Semin Oncol 2002; 29: 361–9.

37.

Clark

W.H.

Jr , From

, Bernardino

E.A.

. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969; 29: 705–27.

38.

Azzola

M.F.

, Shaw

H.M.

, Thompson

J.F.

. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer Causes Control 2003; 97: 1488–98.

39.

Wandel

, Raschke

, Hildebrandt

. Fibroblasts enhance the invasive capacity of melanoma cells in vitro. Arch Dermatol Res 2002; 293: 601–8.

40.

Loffek

, Zigrino

, Angel

. High invasive melanoma cells induce matrix metalloproteinase-1 synthesis in fibroblasts by interleukin-1alpha and basic fibroblast growth factor-mediated mechanisms. J Invest Dermatol 2005; 124: 638–43.

41.

Herlyn

, Padarathsingh

, Chin

. New approaches to the biology of melanoma: a workshop of the National Institutes of Health Pathology B Study Section. Am J Pathol 2002; 161: 1949–57.

42.

Chang

, Werb

. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 2001; 11: S37–43.

43.

Alessandro

, Kohn

E.C.

. Signal transduction targets in invasion. Clin Exp Metastasis 2002; 19: 265–73.

44.

Hofmann

U.B.

, Eggert

A.A.

, Blass

. Expression of matrix metalloproteinases in the microenvironment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation. Cancer Res 2003; 63: 8221–5.

45.

van den Oord

J.J.

, Paemen

, Opdenakker

. Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. Am J Pathol 1997; 151: 665–70.

46.

Heikkila

, Teronen

, Moilanen

. Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines. Anticancer Drugs 2002; 13: 245–54.

47.

L.L.

, Chen

W.J.

, Lin-Shiau

S.Y.

. Penta-O-galloyl-beta-D-glucose inhibits the invasion of mouse melanoma by suppressing metalloproteinase-9 through down-regulation of activator protein-1. Eur J Pharmacol 2002; 453: 149–58.

48.

Mansour

A.M.

, Drevs

, Esser

. A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Cancer Res 2003; 63: 4062–6.